Agreement will allow BE to manufacture heparin- and chondroitin-related carbohydrate therapies.



Heparinex and Choncept entered into option and license agreements with Biological E. (BE), a biopharmaceutical company based in India. The agreement reportedly provides BE with an option for novel production technologies for both heparin- and chondroitin-related carbohydrate compounds.


Heparinex is focused on development of novel recombinant synthesis of compounds for the anticoagulation market to replace the current heparin source of beef and other animal byproducts. Choncept works on the development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products.








This site uses Akismet to reduce spam. Learn how your comment data is processed.